GOODTCELL CO LTD has a total of 15 patent applications. It increased the IP activity by 250.0%. Its first patent ever was published in 2017. It filed its patents most often in Republic of Korea. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are FORNIX BIOSCIENCES N V, FUNDACIO PRIVADA INST DE RECERCA DE LA SIDA CAIXA and MEDIGENE IMMUNOTHERAPIES GMBH.
# | Country | Total Patents | |
---|---|---|---|
#1 | Republic of Korea | 15 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Microorganisms | |
#5 | Analysing materials | |
#6 | Measuring microorganism processes | |
#7 | Specific use of cosmetics |
# | Name | Total Patents |
---|---|---|
#1 | Kim Jung Ho | 12 |
#2 | Kim Beom Seok | 12 |
#3 | Lee Sang Kyou | 5 |
Publication | Filing date | Title |
---|---|---|
KR20200035924A | Use of a novel transmembrane protein of Lrig-1 in a regulatory T cell | |
KR20190027808A | Use of a novel transmembrane protein of Lrig-1 in a regulatory T cell | |
KR20190027809A | Use of a novel transmembrane protein of Lrig-1 in a regulatory T cell | |
KR20180116924A | A polypeptide epitope of extracellular protein of immune cell | |
KR20180116925A | Pharmaceutical composition for preventing and treating cancer or immune disease |